Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Role of Helicobacter Pylori and Its Toxins in Pulmonary and Oropharyngeal Disease
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Listed as NCT00366509, this observational or N/A phase trial focuses on Asthma and Lymphangioleiomyomatosis and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 20 times since 2006, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
20 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Sep 2021 — Jul 2024 [monthly]
Completed
-
May 2021 — Sep 2021 [monthly]
Completed
-
Apr 2021 — May 2021 [monthly]
Completed
▶ Show 15 earlier versions
-
Mar 2021 — Apr 2021 [monthly]
Completed
-
Jan 2021 — Mar 2021 [monthly]
Completed
-
Dec 2020 — Jan 2021 [monthly]
Completed
-
Nov 2020 — Dec 2020 [monthly]
Completed
-
Oct 2020 — Nov 2020 [monthly]
Completed
-
Sep 2020 — Oct 2020 [monthly]
Completed
-
Aug 2020 — Sep 2020 [monthly]
Completed
-
Jul 2020 — Aug 2020 [monthly]
Completed
-
Jun 2020 — Jul 2020 [monthly]
Completed
-
Oct 2019 — Jun 2020 [monthly]
Completed
-
Oct 2018 — Oct 2019 [monthly]
Completed
-
Sep 2018 — Oct 2018 [monthly]
Completed
-
Jun 2018 — Sep 2018 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Sep 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
For direct contact, visit the study record on ClinicalTrials.gov .